- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05411757
IBR900 Cell Injection Combined With Lenvatinib or Bevacizumab in the Treatment of Advanced Primary Liver Cancer
A Single-Arm, Open-Label Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of IBR900 Cell Injection Combined With Lenvatinib or Bevacizumab in the Treatment of Subjects With Advanced Primary Liver Cancer
Study Overview
Status
Conditions
Detailed Description
Two treatment groups are set up in this study. The first treatment group is IBR900 cell injection combined with Lenvatinib. The second treatment group is IBR900 cell injection combined with bevacizumab. Each cycle of the two treatment groups is 21 days. After 4 cycles of treatment, if the investigator judges that the subjects may benefit from continuing treatment, the subjects can continue to receive more cycles of treatment. 6 subjects are enrolled in each treatment group, and the group assignment of subjects is determined by the investigator.
For subjects who have previously received Lenvatinib, they will not be able to continue to receive Lenvatinib after entering the study, but can be treated in combination with bevacizumab. For subjects who have previously received bevacizumab, they will not be able to continue to receive bevacizumab after entering the study, but can be treated in combination with Lenvatinib.
Study Type
Enrollment (Anticipated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Xiaodi Li
- Phone Number: +8617860107786
- Email: sdgwzx2022@163.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female, age≥18 and ≤75 years old.
- Subjects with stage IIb, # or IV unresectable / advanced primary hepatocellular carcinoma, intrahepatic cholangiocarcinoma or mixed hepatocellular cholangiocarcinoma diagnosed in accordance with the Guidelines for Diagnosis and Treatment of Primary Liver Cancer of CSCO(2020 Edition).
- Having ≥ 1 measurable lesion in accordance with the modified Response Evaluation Criteria in Solid Tumors (mRECIST) (lesions located in the field of previous radiation therapy cannot be used as target lesions unless there is imaging evidence that the lesion has progressed or persisted three months after radiation therapy).
- Have a performance status of 0 or 2 on the ECOG Performance Score, life expectancy ≥12 weeks.
- Male and female subjects of childbearing age and their partners must agree to take effective birth controls (hormone, barrier method or abstinence, etc.) from signing the ICF to 6 months after the last administration.
- Subjects should voluntarily participate in this clinical study, are fully aware of the study, have signed the Informed Consent Forms, and are willing to follow and able to complete all trial procedures.
Exclusion Criteria:
- Received systemic anti-tumor therapy within 4 weeks prior to the first administration, including chemotherapy, immunotherapy, radical radiotherapy, etc.; received palliative radiotherapy within 2 weeks prior to the first administration; or the adverse events caused by previous anti-tumor therapy have not recovered to ≤Grade 1 (except for alopecia).
- Have known central nervous system metastases with clinical symptoms.
- Received any adoptive cellular immunotherapy within 6 months prior to the first administration.
- Have undergone major organ surgery (excluding needle biopsy or surgery related to this indication) within 4 weeks prior to their first administration of the study drug, or required elective surgery during the study period.
- Have received or expected to receive glucocorticoids (prednisone >10 mg daily or equivalents) or other immunosuppressive medications within 14 days prior to the first administration. Note: For subjects without active autoimmune disorder, inhaled or topical steroid hormone or equivalent dose of prednisone ≤ 10 mg/day is allowed, and glucocorticoid is allowed for short-term (≤ 7 days) preventive treatment (e.g. contrast media allergy) or for the treatment of non-autoimmune disorder (e.g. delayed type hypersensitivity to contact allergens).
- Received live or attenuated vaccine within 4 weeks prior to the first administration or plan to receive live or attenuated vaccine during the study period.
- Patients with severe infections that cannot be controlled.
- Patients with a known history of human immunodeficiency virus (HIV) active infection.
- Have active autoimmune diseases or have had autoimmune diseases that are likely to recur (e.g., systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, autoimmune thyroid disease, vasculitis, psoriasis, etc.). Except in the following cases: type 1 diabetes well controlled with hormone replacement therapy, hypothyroidism, skin conditions not requiring systemic therapy (such as vitiligo), and other conditions that are well controlled and that are less likely to relapse as by the investigator (such as resolved childhood asthma).
Organ function during screening should meet the following criteria:
- Absolute neutrophil count (ANC)<1.5×10^9/L, platelet (PLT)<75×10^9/L, hemoglobin (Hb)<80g/L, (blood transfusion, platelet and colony stimulating factor therapy are not allowed within 2 weeks before the test);
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)>5 times the upper limit of normal (ULN), and total serum bilirubin>2.5 times the upper limit of normal (ULN);
- Creatinine(Cr)>1.5×ULN, and creatinine clearance rate(Ccr) ≤ 60ml/min (estimated according to Cockcroft-Gault formula). Note: Ccr to be calculated only when Cr >1.5×ULN;
- International normalized ratio (INR) ≤ 2.0×ULN, activated partial thrombin time (APTT) >1.5×ULN.
Have a history of serious cardiovascular and cerebrovascular diseases, including but not limited to:
- There are serious cardiac rhythm or conduction abnormalities, such as ventricular arrhythmia, and Ⅱ-Ⅲ degree atrioventricular block, which need clinical intervention;
- The mean QT interval corrected by Fridericia method (QTcF) is prolonged (male>450ms, female>470ms);
- Acute coronary syndrome, congestive heart failure, aortic dissection, stroke, or other grade 3 or above cardiovascular and cerebrovascular events occurring within 6 months before the first administration;
- Patients with heart failure or left ventricular ejection fraction (LVEF) < 50% in the New York Heart Association (NYHA) classification ≥II;
- Hypertension beyond clinical control;
- Subjects with previous or current interstitial lung disease, pneumoconiosis, radiation pneumonia, severe impairment of pulmonary function that may interfere with the detection and treatment of suspected drug-related pulmonary toxicity. Or uncontrolled systemic diseases, including diabetes, etc.
- Had other malignant tumors in the past 3 years, except for any type of carcinoma in situ that has been cured in the past and cured skin basal cell carcinoma or skin squamous cell carcinoma.
- Pregnant women or lactating women.
- Have a history of drug abuse.
- Patients with a history of serious dementia, mental status changes or any history of mental disorder, incapacity or limited capacity.
- Have participated in other clinical trials and received any unmarketed investigational drug or treatment within 4 weeks prior to the first administration.
- Patients who have received anti-tumor treatment with lenvatinib and bevacizumab.
- According to the judgment of the investigators, other factors that may make the subjects unsuitable for the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: IBR900 cell injection
IBR900 Cell Injection Combined With Lenvatinib or Bevacizumab
|
IBR900 cell injection: 4.0×10^9 cells, D1,D3 of each cycle.
Lenvatinib: body weight ≥ 60kg, 12mg/qd; body weight < 60kg, 8mg/qd; administered continuously from D5 of the first cycle
IBR900 cell injection: 4.0×10^9 cells, D1,D3 of each cycle.
Bevacizumab:15mg/kg, D1 of each cycle.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events (AEs)
Time Frame: From day 1 to day 90 after the last infusion
|
The incidence and severity of adverse events assessed according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0, and the correlation between adverse events and IBR900 cell injection.
|
From day 1 to day 90 after the last infusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate (ORR)
Time Frame: Up to 1 year after infusion
|
The proportion of subjects with complete and partial tumor remissions after treatment
|
Up to 1 year after infusion
|
Progression-free survival (PFS)
Time Frame: Up to 1 year after infusion
|
The time from the beginning of treatment to the onset of tumor progression or death from any cause
|
Up to 1 year after infusion
|
Overall survival (OS)
Time Frame: Up to 5 year after infusion
|
From the beginning of treatment to the time of death from any cause
|
Up to 5 year after infusion
|
Disease control rate (DCR)
Time Frame: Up to 1 year after infusion
|
Proportion of subjects with complete, partial response and stable disease
|
Up to 1 year after infusion
|
Best of response (BOR)
Time Frame: Up to 1 year after infusion
|
The rate of best of disease response recorded from the beginning of study treatment to disease progression, recurrence, or death.
|
Up to 1 year after infusion
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cytokine release
Time Frame: Up to 1 year after infusion
|
Blood samples will be collected at specified time points to detect the cytokine (IL-1β, IL-2, IL-4, IL-6, IL-10, IFN-γ, TNF-α) concentration
|
Up to 1 year after infusion
|
Lymphocyte subtype
Time Frame: Up to 1 year after infusion
|
Blood samples will be collected at specified time points to analyze the lymphocyte subtypes (CD3, CD4, CD8, CD19, CD56)
|
Up to 1 year after infusion
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jingbo Wang, Head of the department of Biology and Cell therapy
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Digestive System Neoplasms
- Liver Diseases
- Liver Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Protein Kinase Inhibitors
- Bevacizumab
- Lenvatinib
Other Study ID Numbers
- IBR900-T02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Primary Liver Cancer
-
University of HawaiiGlaxoSmithKlineRecruitingAdvanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Adult Primary Liver CancerUnited States
-
BeiJing Yijiayi Medicine Techonoloy Co., Ltd.Dalian Holley Kingkong Pharmaceutical Co., LtdUnknownAdvanced Primary Liver CancerChina
-
University of CincinnatiActive, not recruitingLiver Metastases | Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver CancerUnited States
-
BeiJing Yijiayi Medicine Techonoloy Co., Ltd.Dalian Holley Kingkong Pharmaceutical Co., LtdUnknown
-
Zhu XuUnknownAdvanced Adult Primary Liver CancerChina
-
Jiangsu HengRui Medicine Co., Ltd.CompletedAdvanced Biliary Tract Carcinoma | Advanced Primary Liver CancerChina
-
National Cancer Institute (NCI)CompletedAdvanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedAdvanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedAdvanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Adult Primary Hepatocellular CarcinomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedAdvanced Adult Primary Liver Cancer | Localized Resectable Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular CarcinomaUnited States
Clinical Trials on IBR900 combined with Lenvatinib
-
Shanghai Junshi Bioscience Co., Ltd.Active, not recruitingAdvanced Hepatocellular Carcinoma (HCC)Italy, Poland, Singapore, United States, China, Ukraine
-
Shanghai Zhongshan HospitalActive, not recruitingCholangiocarcinoma, IntrahepaticChina
-
Tianjin Medical University Cancer Institute and...Not yet recruitingResectable Hepatocellular CarcinomaChina
-
Sichuan UniversityNot yet recruitingCarrelizumab Plus Lenvatinib Combined With TACE | Borderline Resectable Hepatocellular CarcinomaChina
-
Sun Yat-sen UniversityRecruitingClear Cell Renal Cell Carcinoma | Neoadjuvant Therapy | CadonilimabChina
-
Sun Yat-sen UniversityNot yet recruitingRenal Cell CarcinomaChina
-
Second Affiliated Hospital of Guangzhou Medical...CompletedHepatocellular Carcinoma Non-resectableChina
-
Tianjin Medical University Cancer Institute and...Not yet recruitingObjective Response Rate (ORR)
-
Sun Yat-sen UniversityRecruiting
-
Tianjin Medical University Cancer Institute and...UnknownHepatocellular Carcinoma Non-resectableChina